Skip to main content

Table 1 NIRS variables at end point between placebo and loratadine during +Gz exposure with GOR and ROR.

From: A new evaluation method for +Gz tolerance with loratadine by using a near-infrared spectroscopy

  GOR ROR
NIRS Variable Relaxed Straining Straining
  Placebo Loratadine Placebo Loratadine Placebo Loratadine
ΔO 2 Hb (μmol·L -1 ) -10.5 ± 5.6 -11.1 ± 5.7 -17.4 ± 8.1 -16.9 ± 7.4 -14.7 ± 7.2 -15.0 ± 6.4
ΔHHb (μmol·L -1 ) 0.5 ± 2.4 -0.1 ± 3.4 2.8 ± 1.2 1.4 ± 4.6 0.7 ± 3.0 1.9 ± 3.7
ΔcHb (μmol·L -1 ) -11.3 ± 6.8 -12.8 ± 8.6 -13.2 ± 6.8 -15.5 ± 12.6 -13.6 ± 7.0 -12.0 ± 7.6
TOI% 67.6 ± 4.5 70.2 ± 6.4 64.8 ± 3.7 67.2 ± 6.9 63.5 ± 4.8 66.3 ± 5.7
Baseline 72.4 ± 4.7 73.6 ± 5.1    72.2 ± 4.9 73.7 ± 4.7
ΔTOI% -4.8 ± 2.5 -3.3 ± 3.2 -7.6 ± 2.2 -6.4 ± 4.0 -8.8 ± 1.5 -7.4 ± 3.1
  1. Values are means ± standard deviation. NIRS: near-infrared spectroscopy, GOR: gradual onset run, ROR: rapid onset run, O2Hb: oxygenated hemoglobin, HHb: deoxygenated hemoglobin, cHb: O2Hb + HHb, TOI: tissue oxygenation index, Δ: change.